Back to top

gene-editing: Archive

Sundeep Ganoria

Will AbbVie's Acquisition Spree Aid Pipeline Growth?

ABBV's $2.1 billion Capstan deal and 20+ recent acquisitions sharpen its pipeline edge across immunology and beyond.

SNYNegative Net Change LLYPositive Net Change ABBVNegative Net Change

Sundeep Ganoria

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?

CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.

REGNNegative Net Change VRTXPositive Net Change NTLAPositive Net Change CRSPPositive Net Change

Ahan Chakraborty

What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?

LLY's $1.3 billion Verve deal marks its third M&A in 2025 as it pushes to diversify across cardiovascular, neuro and cancer therapies.

SNYNegative Net Change NVONegative Net Change LLYPositive Net Change VERVPositive Net Change